Objective To explore the role of serum fibrotic indices including hyaluronic acid (HA), procollagen type III NH_ 2-terminal peptide (PCIIIP), and laminin (LN) in assessing the severity of myocardial fibrosis in chroni...Objective To explore the role of serum fibrotic indices including hyaluronic acid (HA), procollagen type III NH_ 2-terminal peptide (PCIIIP), and laminin (LN) in assessing the severity of myocardial fibrosis in chronic congestive heart failure (CHF).Methods Serum levels of HA, PCIIIP, and LN in 39 patients with CHF[14 with New York Heart Association (NYHA) functional class II, 21 with class III, 4 with class IV]and in 46 patients with NYHA functional class I were assessed by radioimmunoassay.Results The serum concentrations of HA, PCIIIP, and LN were 359.75±84.59 μg/L, 77.88±24.67 μg/L, 86.73±23.90 μg/L in CHF group, and 211.60±54.80 μg/L, 64.82±23.99 μg/L, 82.26±23.98 μg/L in NYHA functional class I group, respectively. The HA level was significantly higher in CHF patients as compared with NYHA functional class I group (P<0.05). However, no difference was found in the levels of PCIIIP and LN between CHF group and NYHA functional class I group. The serum HA concentration was negatively correlated with left ventricular ejection fraction (r=-0.71, P<0.05).Conclusion Serum HA level may act as an indicator for myocardial fibrosis.展开更多
AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 female...AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 females) aged 40-66 years(mean 53±13 years) participated in the study.The patients were affected by chronic liver diseases with cirrhosis which was proven histologically(n=58);by chronic active hepatitis C(n=4),chronic active hepatitis B(n=2),and chronic persistent hepatitis C(n=6).In the four patients lacking histology,cirrhosis was diagnosed from anamnesis,serum laboratory tests,esophageal varices and ascites.Patients were assigned to colchicine(1 mg/d) or standard treatment as control in a randomized,double-blind trial,and followed for 4.4 years with clinical and laboratory evaluation.RESULTS:Survival at the end of the study was 94.6% in the colchicine group and 78.4% in the control group(P=0.001).Serum N-terminal peptide of type Ⅲ procollagen levels fell from 34.0 to 18.3 ng/mL(P=0.0001),and pseudocholinesterase levels rose from 4.900 to 5.610 mU/mL(P=0.0001) in the colchicine group,while no signif icant change was seen in controls.Best results were obtained in patients with chronic hepatitis C and in alcoholic cirrhotics.CONCLUSION:Colchicine is an effective and safe antifibrotic drug for long-term treatment of chronic liver disease in which fi brosis progresses towards cirrhosis.展开更多
目的分析血浆B型0脑钠肽(natriuretic peptide,BNP)及血清前Ⅲ型胶原(procollagen type Ⅲ,PCⅢ)对不同左心室舒张充盈类型的原发性高血压(高血压)患者的影响。方法入选高血压患者150例,均无收缩功能障碍,根据左心室舒张充盈类型不同分...目的分析血浆B型0脑钠肽(natriuretic peptide,BNP)及血清前Ⅲ型胶原(procollagen type Ⅲ,PCⅢ)对不同左心室舒张充盈类型的原发性高血压(高血压)患者的影响。方法入选高血压患者150例,均无收缩功能障碍,根据左心室舒张充盈类型不同分为正常舒张充盈型组、松驰受损型组、假正常充盈型组、限制性充盈型组,所有患者均行多普勒超声心动图检查,用干式快速免疫荧光法定量测定血浆B型BNP浓度,用放射免疫法测定血清PCⅢ浓度。结果①正常舒张充盈型组、松弛受损型组、假正常充盈型组、限制性充盈型组的B型BNP分别为(47±16)pg/mL、(147±24)pg/mL、(206±51)pg/mL、(357±64)pg/ml;正常舒张充盈型组、松弛受损型组、假正常充盈型组、限制性充盈型组PCⅢ分别为(81.5±31.4)μg/L、(107.8±30.8)μg/L、(125.3±37.3)μg/L、(157.4±55.4)μg/L,以限制性充盈型组增高最显著,方差分析显示B型BNP与PCⅢ在高血压患者4组间的差异有统计学意义(F=406.6,P<0.05;F=25.4,P<0.05)。②血浆B型BNP与血清PCⅢ呈正相关(r=0.580,P<0.05)。结论血浆B型BNP及血清PCⅢ可客观反映无收缩功能障碍的高血压患者左心室舒张功能受损程度。展开更多
目的应用甘利欣治疗慢性乙型肝炎32例,观察其临床疗效及抗肝纤维化的治疗作用。方法 32例患者均为住院病人,入院后予甘利欣注射液150mg 加入10%葡萄糖液中静滴,每日一次,疗程1～2个月,当 ALT 降至正常后改用甘利欣胶囊口服,每次3粒,每日...目的应用甘利欣治疗慢性乙型肝炎32例,观察其临床疗效及抗肝纤维化的治疗作用。方法 32例患者均为住院病人,入院后予甘利欣注射液150mg 加入10%葡萄糖液中静滴,每日一次,疗程1～2个月,当 ALT 降至正常后改用甘利欣胶囊口服,每次3粒,每日3次,连续服3个月,治疗中密切观察临床症状,并于治疗前后分别检测血清Ⅲ型前胶原肽(PⅢP)和透明质酸(HA),定期检测肝功能。结果疗程结束后治疗组血清 PⅢP 和 HA 含量分别由204.7±72.3μg/l,245.6±100.6μg/l 下降至117.9±56.5μg/l。138.2±68.1μg/l(P<0.01);而对照组血清 PⅢP 和 HA 含量分别由212.4±95.6μg/l,254.4±121.3μg/l 下降至207.4±89.2μg/l,230.2±115.5μg/l(P>0.05)。结论甘利欣可以减轻慢性乙型肝炎患者肝纤维化的程度和活动度,具有一定的抗肝纤维化作用。展开更多
文摘Objective To explore the role of serum fibrotic indices including hyaluronic acid (HA), procollagen type III NH_ 2-terminal peptide (PCIIIP), and laminin (LN) in assessing the severity of myocardial fibrosis in chronic congestive heart failure (CHF).Methods Serum levels of HA, PCIIIP, and LN in 39 patients with CHF[14 with New York Heart Association (NYHA) functional class II, 21 with class III, 4 with class IV]and in 46 patients with NYHA functional class I were assessed by radioimmunoassay.Results The serum concentrations of HA, PCIIIP, and LN were 359.75±84.59 μg/L, 77.88±24.67 μg/L, 86.73±23.90 μg/L in CHF group, and 211.60±54.80 μg/L, 64.82±23.99 μg/L, 82.26±23.98 μg/L in NYHA functional class I group, respectively. The HA level was significantly higher in CHF patients as compared with NYHA functional class I group (P<0.05). However, no difference was found in the levels of PCIIIP and LN between CHF group and NYHA functional class I group. The serum HA concentration was negatively correlated with left ventricular ejection fraction (r=-0.71, P<0.05).Conclusion Serum HA level may act as an indicator for myocardial fibrosis.
文摘AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 females) aged 40-66 years(mean 53±13 years) participated in the study.The patients were affected by chronic liver diseases with cirrhosis which was proven histologically(n=58);by chronic active hepatitis C(n=4),chronic active hepatitis B(n=2),and chronic persistent hepatitis C(n=6).In the four patients lacking histology,cirrhosis was diagnosed from anamnesis,serum laboratory tests,esophageal varices and ascites.Patients were assigned to colchicine(1 mg/d) or standard treatment as control in a randomized,double-blind trial,and followed for 4.4 years with clinical and laboratory evaluation.RESULTS:Survival at the end of the study was 94.6% in the colchicine group and 78.4% in the control group(P=0.001).Serum N-terminal peptide of type Ⅲ procollagen levels fell from 34.0 to 18.3 ng/mL(P=0.0001),and pseudocholinesterase levels rose from 4.900 to 5.610 mU/mL(P=0.0001) in the colchicine group,while no signif icant change was seen in controls.Best results were obtained in patients with chronic hepatitis C and in alcoholic cirrhotics.CONCLUSION:Colchicine is an effective and safe antifibrotic drug for long-term treatment of chronic liver disease in which fi brosis progresses towards cirrhosis.
文摘目的分析血浆B型0脑钠肽(natriuretic peptide,BNP)及血清前Ⅲ型胶原(procollagen type Ⅲ,PCⅢ)对不同左心室舒张充盈类型的原发性高血压(高血压)患者的影响。方法入选高血压患者150例,均无收缩功能障碍,根据左心室舒张充盈类型不同分为正常舒张充盈型组、松驰受损型组、假正常充盈型组、限制性充盈型组,所有患者均行多普勒超声心动图检查,用干式快速免疫荧光法定量测定血浆B型BNP浓度,用放射免疫法测定血清PCⅢ浓度。结果①正常舒张充盈型组、松弛受损型组、假正常充盈型组、限制性充盈型组的B型BNP分别为(47±16)pg/mL、(147±24)pg/mL、(206±51)pg/mL、(357±64)pg/ml;正常舒张充盈型组、松弛受损型组、假正常充盈型组、限制性充盈型组PCⅢ分别为(81.5±31.4)μg/L、(107.8±30.8)μg/L、(125.3±37.3)μg/L、(157.4±55.4)μg/L,以限制性充盈型组增高最显著,方差分析显示B型BNP与PCⅢ在高血压患者4组间的差异有统计学意义(F=406.6,P<0.05;F=25.4,P<0.05)。②血浆B型BNP与血清PCⅢ呈正相关(r=0.580,P<0.05)。结论血浆B型BNP及血清PCⅢ可客观反映无收缩功能障碍的高血压患者左心室舒张功能受损程度。
文摘目的应用甘利欣治疗慢性乙型肝炎32例,观察其临床疗效及抗肝纤维化的治疗作用。方法 32例患者均为住院病人,入院后予甘利欣注射液150mg 加入10%葡萄糖液中静滴,每日一次,疗程1～2个月,当 ALT 降至正常后改用甘利欣胶囊口服,每次3粒,每日3次,连续服3个月,治疗中密切观察临床症状,并于治疗前后分别检测血清Ⅲ型前胶原肽(PⅢP)和透明质酸(HA),定期检测肝功能。结果疗程结束后治疗组血清 PⅢP 和 HA 含量分别由204.7±72.3μg/l,245.6±100.6μg/l 下降至117.9±56.5μg/l。138.2±68.1μg/l(P<0.01);而对照组血清 PⅢP 和 HA 含量分别由212.4±95.6μg/l,254.4±121.3μg/l 下降至207.4±89.2μg/l,230.2±115.5μg/l(P>0.05)。结论甘利欣可以减轻慢性乙型肝炎患者肝纤维化的程度和活动度,具有一定的抗肝纤维化作用。
